B · Normal
[The State Food and Drug Administration approves the marketing of rizabrutinib tablets] On September 3, the State Food and Drug Administration approved the listing of the Class 1 innovative drug rizabrutinib tablets (trade name: Cerizate) applied by Genzyme Corporation. The drug is used for adult patients with persistent or chronic primary immune thrombocytopenia (ITP) who have previously had poor response or intolerance to glucocorticoids, immune globulin and other treatments. The launch of this drug provides patients with new treatment options.
Comments